Navigation Links
Conference report highlights new research into drug delivery to treat eye disease
Date:11/17/2008

Rockville, MD Researchers are investigating microneedles, nanoparticles and polymer carriers as potential new techniques to combat the leading cause of visual impairment and blindness in the United States, according to a report from the Third Annual ARVO/Pfizer Ophthalmics Research Institute Conference.

The report (http://www.iovs.org/cgi/content/full/49/11/4712) includes summaries from seven sessions on techniques for ocular drug delivery to the posterior segment of the eye and includes the findings of and opinions of more than 30 top ophthalmic researchers, brought together by the ARVO Foundation for Eye Research. The article in the November issue of Investigative Opthalmology & Visual Science defines the current research and the future needs for ocular drug delivery.

Diseases of the posterior segment of the eye are responsible for the majority of visual impairment and blindness cases in the United States, according to George Williams, MD. Until recently, these diseases were primarily treated with surgery, but recent developments in drug therapies have either replaced or complemented surgery.

But the challenge lies in delivering the drugs. Topical delivery such as ointments and drops are fairly ineffective, and delivery via intravitreous injection (an injection into the fluid in the behind the lens in the eye) can be hard on the patient. According to the report, "Improved drug delivery technologies that provide optimal pharmacokinetics, dose intervals and less invasive routes of administration are needed."

During the two-day event, John Heckenlively, MD, joined Jayakrishna Ambarti, MD, in a session on animal models of posterior ocular diseases. Allan Hoffman, ScD, discussed the design of polymer carriers for intracellular delivery of biomolecular drugs, such as peptides, proteins and nucleic acid drugs. His group is focused on using a family of acid-sens
'/>"/>

Contact: Jo Olson
jolson@arvo.org
240-221-2923
Association for Research in Vision and Ophthalmology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
4. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)...everseAges.com launches new content to include inf...e, and how to best deal with these health issues. ...uly 3, 2009 -- ReverseAges.com has recently launch...dangers of common health issues such as high blood...ety of factors, and the new content on ReverseAges...
(Date:7/3/2009)...s the health care reform details emerge, more entr... small groups and business insurance premiums. Now... websites such as the Small Business Health Insura... Minneapolis, Minn. (PRWEB) July 3, 2009 --...by the House, which has entrepreneurs worried abou...
(Date:7/2/2009)...2 Acetaminophen is an i...ription medicines to help relieve pain and reduce ...and name, Tylenol and prescription brand names, Vi...for the FDA met on June 30, 2009 to address liver ... The committee voted 20-17 to urge the FDA to put ...
(Date:7/2/2009)...RNewswire-USNewswire/ -- A new analysis of the inc... between the ages of 0 to 84 from 2000 to 2005 sho...ued by the Ministry of Health, with the sharpest u... studied (ages 25 to 44). , , The new results, ... major breast surgeries rather than official estim...
Breaking Medicine News(10 mins):Health News:Health Care Reform Details Emerge with 'Play or Pay' Requirements, Leaving Some Wondering about Small Business Owner Insurance 2Health News:Health Care Reform Details Emerge with 'Play or Pay' Requirements, Leaving Some Wondering about Small Business Owner Insurance 3Health News:Viles & Beckman, LLC: Stop Your Headache NOT Your Liver 2Health News:Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 2Health News:Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 3
...lu related death has been reported in Egypt, the m...minations revealed that the 30 year old woman //, ...nic H5N1 strain of bird flu. The victim from Nawa...h of here, died early Friday morning in a Cairo ho...
...ratory equipped to handle the avian influenza H5N1...y. Tiny vials of chicken blood and poultry tissue ...mples are sent by the farmers from places that exp...routine surveillance sites. Veterinary pathologi...
...osuppressant, meant for use in kidney transplant r...in disorder. The drug was discovered 40 years ago,...anted kidneys// in renal failure patients. In aro...zathioprine prevented the rejection of canine kidn...
...velopment of prosthetic limbs researchers at Unive...rength muscles which are powered by alcohol and hy...cial muscles are 100 times more powerful than the ...le are being investigated by US researchers at the...
Other Medicine News:Health News:Azathioprine Can Soon Revolutionize Eczema Treatment 2
(Date:6/28/2009)...CHMOND, Calif., June 29 ...announced that a key research milestone has been a... Genentech, Inc., a wholly-owned member of the Roc...vel characteristics for pharmaceutical protein pro...finger DNA-binding protein nuclease (ZFN) technolo...
(Date:6/26/2009)...ERFIELD, Ill., June 26, and OSAKA, Japan, June 27,...y Limited ("Takeda") today announced that Takeda G...holly owned United States (U.S.) subsidiary receiv...er from the U.S. Food and Drug Administration (FDA...A) for alogliptin, a selective dipeptidyl peptidas...
(Date:6/26/2009)...Combination of Inherited and New Genetic Mutations...RNewswire-USNewswire/ -- More pieces in the comple...test study from a research team including genetici...the University of Pennsylvania School of Medicin...dy identified 27 different genetic regions where r...
(Date:6/25/2009)...W YORK, June 25 As of m...on,s Research has already funded over $1 million i... therapeutic development through its groundbreakin...lude investigations of the safety and efficacy of ...arkinson,s; characterization of a tenuous link bet...
Breaking Medicine Technology:Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes 2More Gene Mutations Linked to Autism Risk 2More Gene Mutations Linked to Autism Risk 3More Gene Mutations Linked to Autism Risk 4MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease 2MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease 3Eye Related Symptoms Bring More Than Tears to Allergy Sufferers New Survey Reveals 47133 1Eye Related Symptoms Bring More Than Tears to Allergy Sufferers New Survey Reveals 47133 2Eye Related Symptoms Bring More Than Tears to Allergy Sufferers New Survey Reveals 47133 3Aethlon Medical to Present at the 2009 RedChip Small Cap Investor Conference on June 16 2009 4460 1Aethlon Medical to Present at the 2009 RedChip Small Cap Investor Conference on June 16 2009 4460 2Aethlon Medical to Present at the 2009 RedChip Small Cap Investor Conference on June 16 2009 4460 3BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug 4458 1BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug 4458 2CuraGen to Present CR011 vcMMAE Data at ASCO 4457 1CuraGen to Present CR011 vcMMAE Data at ASCO 4457 2CuraGen to Present CR011 vcMMAE Data at ASCO 4457 3CuraGen to Present CR011 vcMMAE Data at ASCO 4457 4CuraGen to Present CR011 vcMMAE Data at ASCO 4457 5
...resented at the American Academy of Neurology Annu... in Partial Seizures, BOSTON, May 01, 2007 /PRNews...oday at the American Academy of Neurology (AAN),me...xtended release,formulation of Lamictal(R) (lamotr...s with partial epilepsy with and without,secondary...
...y of over 7,700 women published today shows reduct...t in hip fractures, EAST HANOVER, N.J., May 02, 20...ast(R) (zoledronic acid) Injection significantly,r...bone fractures,over three years in women with post...ay in The New England Journal of Medicine,marks t...
Other Medicine Technology:New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 2New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 3New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 4New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures 5Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 2Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 3Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 4Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 5Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 6
This compression garment can be used immediatlely following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction Lipectomy, Stomach Liposuction, Liposculpture and Tummy Tuck procedur
CDIs original garments with our exclusive Wonderfabric™.
Below Knee Girdle, High Waist
Short Girdle, High Waist, Mid-thigh
Medicine Products: